ClinicalTrials.Veeva

Menu

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

BeiGene logo

BeiGene

Status and phase

Active, not recruiting
Phase 2

Conditions

Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer

Treatments

Drug: pemetrexed
Drug: Tislelizumab
Drug: BGB-15025
Drug: Carboplatin
Drug: Nab paclitaxel
Drug: BGB-A445
Drug: Cisplatin
Drug: LBL-007
Drug: Paclitaxel

Study type

Interventional

Funder types

Industry

Identifiers

NCT05635708
CTR20230892 (Other Identifier)
2022-502738-18-00 (EU Trial (CTIS) Number)
BGB-LC-201

Details and patient eligibility

About

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (< 50%).

Enrollment

400 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  1. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including nonsquamous or squamous subtypes, that is either locally advanced or recurrent and not eligible for curative surgery and/or definitive chemoradiotherapy, or metastatic NSCLC.
  2. No prior systemic therapy administered as the primary treatment for metastatic NSCLC. Prior adjuvant or neoadjuvant chemotherapy, definitive chemoradiation, or adjuvant radiotherapy for locally advanced disease is permitted, provided the last dose of chemotherapy and/or radiotherapy occurred at least 6 months prior to randomization/enrollment.
  3. Tumor programmed death-ligand 1 (PD-L1) expression must be evaluable, as determined by a local or central laboratory using archival tumor tissue or a fresh biopsy. Participants with unknown PD-L1 expression are not eligible.
  4. At least one measurable lesion, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

Key Exclusion Criteria:

  1. Diagnosis of mixed small cell lung cancer.

  2. Known genomic alterations for which effective targeted therapies are available according to local standard of care, including but not limited to:

    • Epidermal growth factor receptor (EGFR) mutations
    • Anaplastic lymphoma kinase (ALK) rearrangements
    • B-Raf proto-oncogene (BRAF) mutations
    • Rearranged during transfection (RET) fusions
    • c-ros oncogene 1 (ROS1) rearrangements
  3. Participants with nonsquamous NSCLC and unknown EGFR mutation status must undergo local testing. Those found to have EGFR-sensitizing mutations will be excluded.

  4. Prior treatment with immune-based therapies that target immune checkpoint pathways, including:

    • PD-1 (programmed cell death protein 1) inhibitors
    • PD-L1 (programmed death-ligand 1) inhibitors
    • PD-L2 (programmed death-ligand 2) inhibitors
    • TIGIT (T cell immunoreceptor with Ig and ITIM domains) inhibitors
    • LAG-3 (lymphocyte activation gene 3) inhibitors
  5. Participants previously treated with these agents in a neoadjuvant, adjuvant, or consolidation setting may be eligible if a treatment-free interval of at least 6 months has elapsed since the last dose and radiologic evidence of recurrence is present.

  6. Use of Chinese herbal medicines or Chinese patent medicines intended for cancer control within 14 days prior to randomization/enrollment.

  7. Presence of active leptomeningeal disease, untreated or uncontrolled brain metastases, or active autoimmune disease.

Note: Additional protocol-defined and sub-study-specific criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

400 participants in 8 patient groups

Sub-study 1: Arm 1A
Experimental group
Description:
Tislelizumab + BGB-A445
Treatment:
Drug: BGB-A445
Drug: Tislelizumab
Sub-study 1: Arm 2A
Experimental group
Description:
Tislelizumab + LBL-007
Treatment:
Drug: LBL-007
Drug: Tislelizumab
Sub-study 1: Arm 3A
Experimental group
Description:
Tislelizumab + BGB-15025
Treatment:
Drug: BGB-15025
Drug: Tislelizumab
Sub-study 1: Reference Arm Tislelizumab alone
Active Comparator group
Description:
Tislelizumab alone
Treatment:
Drug: Tislelizumab
Sub-study 2: Arm 1B
Experimental group
Description:
Tislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-A445
Treatment:
Drug: Paclitaxel
Drug: Cisplatin
Drug: BGB-A445
Drug: Nab paclitaxel
Drug: Carboplatin
Drug: pemetrexed
Drug: Tislelizumab
Sub-study 2: Arm 2B
Experimental group
Description:
Tislelizumab + investigator's choice of histology-appropriate chemotherapy + LBL-007
Treatment:
Drug: Paclitaxel
Drug: Cisplatin
Drug: LBL-007
Drug: Nab paclitaxel
Drug: Carboplatin
Drug: pemetrexed
Drug: Tislelizumab
Sub-study 2: Arm 3B
Experimental group
Description:
Tislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-15025
Treatment:
Drug: Paclitaxel
Drug: Cisplatin
Drug: Nab paclitaxel
Drug: BGB-15025
Drug: Carboplatin
Drug: pemetrexed
Drug: Tislelizumab
Sub-study 2: Reference Arm
Active Comparator group
Description:
Tislelizumab + investigator's choice of histology-appropriate chemotherapy
Treatment:
Drug: Paclitaxel
Drug: Cisplatin
Drug: Nab paclitaxel
Drug: Carboplatin
Drug: pemetrexed
Drug: Tislelizumab

Trial contacts and locations

66

Loading...

Central trial contact

BeiGene

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems